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Abstract
Background: Hypoxia-Inducible Factor 1 (HIF-1) is a transcription factor that is a critical mediator of the cellular response to
hypoxia. Enhanced levels of HIF-1a, the oxygen-regulated subunit of HIF-1, is often associated with increased tumour
angiogenesis, metastasis, therapeutic resistance and poor prognosis. It is in this context that we previously demonstrated
that under hypoxia, bcl-2 protein promotes HIF-1/Vascular Endothelial Growth Factor (VEGF)-mediated tumour
angiogenesis.
Methodology/Principal Findings: By using human melanoma cell lines and their stable or transient derivative bcl-2
overexpressing cells, the current study identified HIF-1a protein stabilization as a key regulator for the induction of HIF-1 by
bcl-2 under hypoxia. We also demonstrated that bcl-2-induced accumulation of HIF-1a protein during hypoxia was not due
to an increased gene transcription or protein synthesis. In fact, it was related to a modulation of HIF-1a protein expression at
a post-translational level, indeed its degradation rate was faster in the control lines than in bcl-2 transfectants. The bcl-2-
induced HIF-1a stabilization in response to low oxygen tension conditions was achieved through the impairment of
ubiquitin-dependent HIF-1a degradation involving the molecular chaperone HSP90, but it was not dependent on the prolyl
hydroxylation of HIF-1a protein. We also showed that bcl-2, HIF-1a and HSP90 proteins form a tri-complex that may
contribute to enhancing the stability of the HIF-1a protein in bcl-2 overexpressing clones under hypoxic conditions. Finally,
by using genetic and pharmacological approaches we proved that HSP90 is involved in bcl-2-dependent stabilization of HIF-
1a protein during hypoxia, and in particular the isoform HSP90b is the main player in this phenomenon.
Conclusions/Significance: We identified the stabilization of HIF-1a protein as a mechanism through which bcl-2 induces the
activation of HIF-1 in hypoxic tumour cells involving the b isoform of molecular chaperone HSP90.
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Introduction
The transcription factor Hypoxia-Inducible Factor 1 (HIF-1)
regulates the expression of more than 70 genes involved in tumour
angiogenesis, metabolic switch to anaerobic glycolysis, pro-
survival, proliferative and apoptotic mechanisms [1]. Overall,
the expression of HIF-1 target genes helps cells to adapt to, and
thereby survive in, a stressful microenvironment. The activity of
HIF-1 dimer, which is composed of a and b subunits, is modulated
by the availability of the extremely labile oxygen-sensitive HIF-1a
protein subunit. HIF-1 activity depends on the inhibition of the
post-transcriptional hydroxylation of the subunit a by prolyl
hydroxylases PHD1-3 and Factor Inhibiting HIF-1 (FIH-1).
PHDs-mediated hydroxylation targets HIF-1a for proteasomal
degradation via the ubiquitination-dependent Von Hippel-Lindau
(VHL) complex, while FIH-1-mediated hydroxylation leads to the
inhibition of HIF-1 transactivation. The activity of PHD1-3
enzymes is dependent on substrates oxygen and 2-oxoglutarate, a
Krebs cycle intermediate, and cofactor Fe
2+; thus, under hypoxic
conditions, PHDs are less active due to the substrate-limiting
conditions. The regulation of HIF-1a stability by an oxygen-
independent degradation pathway was also reported: the molec-
ular chaperone Heat Shock Protein 90 (HSP90) binds and
stabilizes HIF-1a, competing with Receptor of Activated protein
Kinase C (RACK1), which mediates prolyl hydroxylase/VHL-
independent ubiquitination and proteasomal degradation of HIF-
1a [2]. Other post-translational modifications of HIF-1a, such as
acetylation, phosphorylation and nitrosylation, were also reported,
despite contradictory results with regard to their effect on HIF-1a
protein stability and transcriptional activity [3–6]. Adding to the
complexity of HIF-1a regulation, it has recently been shown that
the SUMOylation of HIF-1a enables the hydroxylation-indepen-
dent binding and subsequent degradation of HIF-1a by the VHL-
E3 ligase complex [7].
Although hypoxia is considered the main stimulus that drives
HIF-1 function, a number of non-hypoxic stimuli allows the
formation of an active HIF-1 complex in many types of human
cancers. Effectors implicated in stimulating or suppressing an
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some autocrine growth factors enhance translation of the HIF-1a
protein [1]. Indeed, the loss of function of tumour suppressors and
the gain of function of oncogenes also regulate different steps that
lead to HIF-1 activation [1,11]. In this context we also found that
overexpression of the anti-apoptotic and pro-survival protein bcl-
2, in human melanoma and breast carcinoma cells, under
hypoxia, enhances HIF-1a protein expression and HIF-1 activity
consequently leading to angiogenesis through vascular endothelial
growth factor (VEGF) [12,13]. Moreover, the treatment of
melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide
exterts antiangiogenic activity [14]. We also demonstrated that
bcl-2 plays a role, in cooperation to hypoxia, in cell migration and
invasion, contributing to tumour progression [15,16]. Indeed, a
significant positive correlation between the expression levels of
HIF-1a and bcl-2 was found in neuroblastoma [17].
This study thoroughly investigated the mechanism by which
bcl-2 regulates HIF-1 in tumour cells exposed to hypoxic
conditions. It identified the stabilization of HIF-1a protein as a
mechanism by which bcl-2 induces the activation of HIF-1 in
hypoxic melanoma cells, through the impairment of ubiquitin-
dependent HIF-1a degradation with the involvement of the b
isoform of the molecular chaperone HSP90.
Results
bcl-2 modulation regulates HIF-1a protein expression in
conditions strictly dependent on oxygen availability
We have previously reported that bcl-2 overexpression in
human breast carcinoma and melanoma cell lines increases HIF-1
expression and activity and VEGF secretion under hypoxic
conditions [12,13,18]. The ability of bcl-2 to modulate VEGF
expression under hypoxia has been also extended to several other
human melanoma cell lines (Figure S1A,B). The relevance of
HIF-1a as the main mediator of bcl-2 induced VEGF secretion
under hypoxic conditions has been demonstrated using siRNA
directed to HIF-1a in M14 cells stably transfected with bcl-2
expression vector (Figure S1C). In fact, the down-regulation of
HIF-1a protein reduced VEGF expression both in control cells
and bcl-2 overexpressing clones. Interestingly, after HIF-1a
reduction, VEGF levels secreted by bcl-2 transfectants were
similar to those ones of control cells (Figure S1D). To evaluate
whether down-regulation of bcl-2 shows opposite effect of bcl-2
overexpression in terms of HIF-1a protein expression, we silenced
the endogenous expression of bcl-2 gene transfecting M14 cells
with siRNA-targeting bcl-2 mRNA (si-bcl-2) and then exposing
them to normoxia or hypoxia for 24 h. Western blot analysis
demonstrated that the delivery of si-bcl-2 reduced expression of
bcl-2 protein (Figure 1A) while, as expected, the transfection of a
scrambled si-RNA (si-contr) did not have any effect on bcl-2
protein expression when compared to untransfected parental cell
line (data not shown). Then, we evaluated the impact of reduced
bcl-2 expression on HIF-1a protein expression. As expected, HIF-
1a protein was undetectable in all cells under normoxic
conditions, while an increased HIF-1a protein expression was
observed in the cells exposed to si-contr under hypoxia, but not in
the cells after down-regulation of the bcl-2 protein expression
(Figure 1A).
To further characterize the impact of bcl-2 on HIF-1a
expression, we evaluated whether bcl-2 overexpression was able
to cooperate with other stimuli, beyond hypoxia, known to
modulate HIF-1 a expression [1]. Firstly, we verified if increased
cell density affected the level of HIF-1a protein in M14 cells stably
transfected with empty vector (puro) and in their two derivative
stably bcl-2 overexpressing clones (Bcl2/5, Bcl2/37). As shown in
Figure 1B, while HIF-1a protein is detectable at same extent in
all cell lines plated at low density (sparse), regardless of bcl-2
expression, an increased HIF-1a protein expression was observed
in bcl-2 transfectants, compared to the control line, either when
they were plated at high density (dense) or when they reached high
cell density (4 days of culture) and, as expected and previously
reported [12,18], in hypoxic conditions. HIF-1b was constitutively
expressed in the cells, and none of those stimuli modulated its
expression. Nuclear translocation of HIF-1a subunit is a necessary
step for HIF-1 transcriptional activity through its association with
HIF-1b, which is constitutively localized in the nucleus [1]. In our
experimental model, high cell density conditions induced the
nuclear expression of HIF-1a in bcl-2 overexpressing clones while
its expression was undetectable in control cells (Figure S2A). In
parallel, control cells and bcl-2 overexpressing clones exhibited
density-dependent induction of the HIF-1-dependent transcrip-
tional activity under normoxic conditions of about 2.3 fold
(p=0.039) while HRE-dependent transcriptional activity was not
found to be significantly changed in control cells (p=0.49)
(Figure S2B).
To further investigate the induction of HIF-1a protein observed
in bcl-2 transfectants under high cell density conditions, we
evaluated whether the creation of a local hypoxic microenviron-
ment could be responsible for HIF-1a induction. Hence, the cells
were cultured at high density and gently shaked to disrupt any
potential oxygen gradient due to the inter-cellular environment
and to ensure a homogenous oxygen concentration within the cell
culture medium. As depicted in Figure 1C, the gentle shaking
drastically reduced the high density-dependent HIF-1a induction
in bcl-2 transfectants, thus indicating that oxygen pericellular
gradient is an important factor contributing in the increase of HIF-
1a expression by bcl-2 in high cell density conditions. To confirm
these results, we plated cells in high density conditions with
decreasing volumes of medium, to enhance the oxygen exchange
rate. As shown in Figure 1D, the decrease of culture medium
volume from 4 to 1 ml determined a medium volume-dependent
reduction of HIF-1a protein expression in both bcl-2 transfectants.
Next, we evaluated whether any differences existed between
control cells and bcl-2 overexpressing clones in terms of HIF-1a
induction in response to growth-factor stimulation, another
condition that induces hypoxia-independent HIF-1a expression
even in normoxia [19]. As shown in Figure 1E, both insulin and
the Epidermal Growth Factor (EGF) induced HIF-1a protein
expression in all the cells under normoxia but more importantly no
difference in the levels of HIF-1a protein was observed in bcl-2
transfectants compared to control cells.
bcl-2 promotes HIF-1a protein stability preventing its
ubiquitin-mediated degradation
Since bcl-2 overexpression in melanoma cells under hypoxia did
not alter HIF-1a mRNA levels [12], we investigated the impact of
bcl-2 overexpression on HIF-1a protein stabilization under
hypoxia. Firstly, we performed time course experiments to study
the kinetics of HIF-1a protein induction in control cells and bcl-2
overexpressing clones. As shown in Figure 2A (left and right
panels), exposure of cells to hypoxia determined a HIF-1a protein
induction, at a greater extent in bcl-2 transfectants compared to
control cells, as previously reported. In particular, HIF-1a protein
level reached the maximum value at 24 h of hypoxia in all cell
lines, but it decreased at later time point of 48 h, slower in bcl-2
overexpressing clones than in control cells.
To verify whether bcl-2 enhances HIF-1a protein expression by
affecting its translational rate, we determined the possible
HIF-1a Stabilization by Bcl-2
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using [
35S]-labeled methionine and cysteine in pulse analysis. As
shown in Figure 2B, HIF-1a protein synthesis rate was almost
identical in control cells and bcl-2 overexpressing clones, indicating
that bcl-2 does not affect HIF-1a protein synthesis. Therefore, the
potential role of bcl-2 in the regulation of HIF-1a protein turnover
was analyzed. As depicted in Figure 2C (left and right panels), a
time-dependent decrease of HIF-1a protein level was observed after
treatment with the protein synthesis inhibitor Cyclohexamide
(CHX) following hypoxia exposure, both in control cells and bcl-2
transfectants. Particularly under CHX exposure for 60 min, the
HIF-1a protein was still well detectable in bcl-2 transfectants while
weakly in the control cells. Indeed, bcl-2 overexpression increased
the HIF-1a half-life from 1565 min to 4565 min under hypoxic
conditions (Figure 2C). Similar results were obtained evaluating
the effect of bcl-2 on HIF-1a half-life in high cell density conditions,
where the HIF-1a protein half-life was about 20610 min in control
cells, and increased to 4065 min in bcl-2 transfectants (Figure S3).
We confirmed these results performing pulse-chase experiment, in
which a pulse with [
35S]-labeled methionine and cysteine was
followed by a chase time of varying length (ranging from 15 to
60 min). As shown in Figure 2D, HIF-1a degradation rate was
higher in control cells compared to bcl-2 transfectants, in fact after
45 min ofchase, the HIF-1a protein was stillwell detectablein bcl-2
Figure 1. bcl-2 modulation regulates HIF-1a protein expression in conditions strictly dependent on oxygen avaibility. (A) Western
blot analysis of HIF-1a and bcl-2 protein expression in total extracts of M14 cells transfected with siRNA targeting bcl-2 mRNA (si-bcl-2) or with a
control scrambled si-RNA (si-contr) and then exposed to normoxia or hypoxia for 24 h. (B) Western blot analysis of HIF-1a and HIF-1b protein
expression in total extracts of M14 control (puro) and bcl-2 stably overexpressing (Bcl2/5, Bcl2/37) cells plated under low (sparse) or high (dense) cell
density conditions, or cultured under normoxia for 4 days or under hypoxia for 24 h. Western blot analysis of HIF-1a and HIF-1b protein expression in
total extracts of the cells plated under high cell density conditions and (C) exposed to 24 h shaking or (D) cultured with different volumes of medium.
(E) Western blot analysis of HIF-1a and HIF-1b protein expression in total extracts of cells exposed to Insulin (100 nM) or Epidermal Growth Factor
(EGF, 20 ng/ml) for 24 h. (A–E) b-actin protein amounts are used to check equal loading and transfer of proteins. Western blot analyses representative
of two independent experiments with similar results are shown.
doi:10.1371/journal.pone.0011772.g001
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immunoprecipitation experiments whether the effect of bcl-2 on
HIF-1a stabilization is due to an impairment of HIF-1a
ubiquitination. As shown in Figure 2E, higher levels of
ubiquitinated HIF-1a were found in control cells either treated
with the proteasome inhibitor MG132 under normoxia, either
exposed to hypoxia, when compared to levels of ubiquitinated HIF-
1a found in bcl-2 transfectants exposed to the same conditions.
Taken together, all these data demonstrate that under hypoxia bcl-2
overexpression modulates HIF-1a expression at a post-translational
level through the stabilization of the HIF-1a protein.
bcl-2 protein interacts with HIF-1a protein
To test whether the effect of bcl-2 on the stability of HIF-1a is
due to their functional cooperation, we tested the eventual
interaction between bcl-2 and HIF-1a protein by immunoprecip-
itation experiments. When immunoprecipiatation was carried out
using an antibody against bcl-2 protein and Western blot analysis
was performed using antibodies that specifically recognizing HIF-
1a protein, bcl-2 was found to be immunoprecipitated with HIF-
1a protein in control cells and bcl-2 overexpressing clones after
exposure to hypoxia, even though the bcl-2/HIF-1a immuno-
complex was more evident in bcl-2 transfectants when compared
to control cells (Figure 3A). To confirm the interaction between
endogenous HIF-1a and bcl-2, the cells were treated with MG132
to accumulate similar levels of HIF-1a protein in all the cells, then
immunoprecipitation experiments were performed using an anti-
HIF-1a antibody and the bcl-2/HIF-1a immunocomplex were
analyzed by Western blot using an anti-bcl-2 antibody
(Figure 3B). Under these conditions, in spite of similar levels of
Figure 2. bcl-2 promotes HIF-1a protein stability preventing its ubiquitin-mediated degradation. (A) Western blot analysis (left panel)
and quantification (right panel) of HIF-1a protein expression in M14 control (puro) and bcl-2 stably overexpressing (Bcl2/5, Bcl2/37) clones exposed to
hypoxia for the indicated time. (B) Pulse analysis of HIF-1a protein synthesis rate in cells exposed to [
35S]–labeled methionine and cysteine for the
indicated time. (C) Western blot analysis (left panel) and quantification (right panel) of HIF-1a protein expression in cells exposed to hypoxia for 24 h
and then treated with Cyclohexamide (CHX, 50 mg/ml) for the indicated time. (D) Pulse-chase analysis of HIF-1a protein (left panel) and quantification
(right panel) in cells plated under dense conditions, pulsed for 45 min with [
35S]–labeled methionine and cysteine and chased for the indicated time.
(B,D) Whole cell lysates were immunoprecipitated (IP) with anti-HIF-1a antibody and subjected to SDS-PAGE. (E) Western blot analysis of HIF-1a
ubiquitination in the cells exposed to MG132 (10 mM, 6 h) or to hypoxia for 24 h. Whole cell lysates were immunoprecipitated (IP) with anti-HIF-1a
antibody and then the Western blot analysis was performed using anti-Ubiquitin antibody. (A,C) b-actin protein amounts are used to check equal
loading and transfer of proteins and to quantify relative HIF-1a protein levels. (A–E) Western blot, pulse and pulse-chase analyses representative of
two independent experiments with similar results are shown. (A,C,D) Densitometric analysis (right panel) of the relative Western blot or Pulse-chase
analysis (left panel) was performed using Molecular Analyst Software and normalized with relative controls.
doi:10.1371/journal.pone.0011772.g002
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within the immunoprecipitates in bcl-2 transfectants but only
weakly in control cells, suggesting that HIF-1a interaction with
bcl-2 protein was stronger in bcl-2 overexpressing clones. Similar
results were obtained when immunoprecipitations were performed
using different antibodies recognizing different epitopes on the bcl-
2 and HIF-1a proteins (data not shown). Immunoprecipitation
experiments of HIF-1a protein were also perfomed in two other
melanoma cell lines, JR8 and PLF2, and their bcl-2 derivative
stably clones treated with MG132 obtaining similar results
(Figure 3C,D) and thus generalizing the ability of bcl-2 protein
to interact with HIF-1a protein.
bcl-2 protein interacts with HIF-1a protein in the
nucleoplasm
bcl-2 is primarily localized in the outer mitochondrial
membrane with minor expression in the nucleus and in the
endoplasmatic reticulum [20]. Recent reports indicate that bcl-2
also resides in the nuclear membrane and may even function
within the nucleus [21–24]. On the other hand, HIF-1a protein
induced by hypoxic conditions mainly localizes and elicits its
transcriptional activity in the nucleus [1]. Given that bcl-2 is able
to interact with HIF-1a, we examined the effect of hypoxia on the
intracellular localization of HIF-1a and bcl-2 by using biochemical
fractionation and confocal microscopy. As reported in Figure 4A,
hypoxic conditions induced HIF-1a protein translocation in the
nuclear fraction of both control cells and bcl-2 transfectants, even
though HIF-1a protein expression was higher in bcl-2 transfec-
tants. By contrast, overexpressed bcl-2 protein was expressed in
nuclear and mainly in cytoplasmic compartments, and hypoxia did
not modulate both bcl-2 expression or its cellular localization.
Confocal microscopy (Figure 4B) confirmed that bcl-2 protein is
mainly cytoplasmic but it is also localized in the nuclear envelope,
and hypoxia does not modify bcl-2 localization. As expected, HIF-
1a is mainly localized into the nucleus, it was found to be
organized in spots which co-localized with chromatin, correlated
to an enhanced transcriptional activity of HIF-1a under hypoxia.
Given that hypoxia-induced HIF-1a is mainly localized in the
nuclear compartment, we formulated the hypothesis that bcl-2
may regulate HIF-1a protein stability through the formation of a
protein complex localized in the nucleus. Immunoprecipitation
experiments on isolated nuclear protein extracts showed that bcl-2
was associated with HIF-1a, while undetectable levels of HIF-1a/
bcl-2 complexes were observed in the cytosolic fraction, indicating
that under hypoxia HIF-1a/bcl-2 interaction may only occur in
the nucleus (Figure 4C). Thus, the finding of an interaction
between HIF-1a/bcl-2 proteins in the nucleus suggests that
bcl-2 may act on the stabilization of HIF-1a in this cellular
compartment.
bcl-2 regulates HIF-1a protein stability in a prolyl
hydroxylation-independent manner
Under normoxia, the proline to alanine mutation of residues
402 and 564 of human HIF-1a makes the protein resistant to
PHD-dependent hydroxylation and subsequent VHL-dependent
ubiquitination and degradation [25]. Besides, PHD2 can be active
in the degradation of HIF-1a even under hypoxic conditions
[26,27]. In order to study the impact of bcl-2 on PHD-mediated
Figure 3. bcl-2 interacts with HIF-1a. (A) Analysis of HIF-1a/bcl-2 protein interaction in M14 control (puro) and stably bcl-2 overexpressing (Bcl2/
5, Bcl2/37) clones exposed to hypoxia for 24 h. Whole cell lysates were immunoprecipitated (IP) with anti-bcl-2 or control (IgG) antibodies and then
the Western blot analysis was performed using anti-HIF-1a and anti-bcl-2 antibodies. Analysis of HIF-1a/bcl-2 protein interaction in (B) M14 control
(puro) and stably bcl-2 overexpressing (Bcl2/5, Bcl2/37) clones or (C,D) in PLF2 and JR8 control cells (PLF2/puro, JR8/puro) and stably bcl-2
overexpressing (PLF2/Bcl-2, JR8/Bcl-2) cells, exposed to MG132 (10 mM, 6 h). Whole cell lysates were immunoprecipitated with anti-HIF-1a or control
(IgG) antibodies and then the Western blot analysis was performed using anti-HIF-1a and anti-bcl-2 antibodies. (A–D) b-actin protein amounts are
used to check equal loading and transfer of proteins. Western blot analyses representative of two independent experiments with similar results are
shown.
doi:10.1371/journal.pone.0011772.g003
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expressing wild type form of HIF-1a (HIF-1a wt) or hydroxylation-
resistant (P402A/P564A) form of HIF-1a (HIF-1a PP/AA). These
cells were then transiently transfected with an empty vector or with
a vector encoding bcl-2 protein and HIF-1a expression and
transcriptional activity were analyzed under hypoxic conditions.
As depicted in Figure 5, bcl-2 overexpression significantly
increased the levels of both exogenous wt and hydroxylation-
resistant form of HIF-1a (Figure 5A) and it also enhanced HRE-
dependent transcriptional activity (Figure 5B). As expected,
PHD2 overexpression inhibited the expression of HIF-1a wt and
HRE-dependent transcriptional activity while it did not abrogate
the expression and activation of reporter gene transcription in cells
expressing HIF-1a protein containing the proline-to-alanine
substitutions (Figure 5B). The discovery that bcl-2 had similar
effects on the wt and mutant form of HIF-1a indicated that bcl-2
Figure 4. bcl-2 interacts with HIF-1a in the nucleus. (A) Western blot analysis of bcl-2 and HIF-1a protein expression in nuclear (Nucl) and
cytoplasmic (Cyto) protein extracts of M14 control (puro) and bcl-2 stably overexpressing (Bcl2/5) clones exposed to hypoxia or to normoxia for 24 h.
LaminA/C (Lam A/C) and b-tubulin were used as markers for nuclear and cytoplasmic fraction, respectively. b-actin protein amounts are used to check
equal loading and transfer of proteins. (B) Confocal laser scanning microscopy of immunofluorescence staining performed on Bcl2/5 stably
overexpressing clone exposed to hypoxia or to normoxia for 24 h. Fixed cells were labelled with anti-bcl-2 (green) or anti-HIF-1a (red) antibodies.
Nuclei were visualized using TO-PRO3H staining (blue). (C) Analysis of HIF-1a/bcl-2 interaction in Bcl2/5 stably overexpressing clone exposed to
hypoxia for 24 h. Nuclear (Nucl) and cytoplasmic (Cyto) protein extracts were immunoprecipitated (IP) with anti-HIF-1a or anti-bcl-2, respectively, or
control antibody (IgG) and then the Western blot analysis was performed using anti-bcl-2 or anti-HIF-1a antibodies. (A–C) Western blot and confocal
analyses representative of two independent experiments with similar results are shown.
doi:10.1371/journal.pone.0011772.g004
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ation of HIF-1a. These results are also supported by the findings
that forced expression of bcl-2 had no impact on HIF-1a
stabilization when cells were treated with PHD inhibitors Cobalt
Chloride and Desferoxamine, two iron antagonists known to
inhibit hydroxylase activity (Figure S4).
bcl-2 forms a complex with HSP90 and HIF-1a proteins,
enhancing their interaction and protecting HIF-1a from
degradation mediated by 17-AAG
HSP90 is a molecular chaperone required for the stability and
function of a number of proteins implicated in cancer cell growth
and angiogenesis, including HIF-1a [28]. In particular, it binds and
stabilizes HIF-1a, and it represents a critical factor in an O2/PHD/
VHL-independent degradation pathway of HIF-1a protein [2]. To
evaluate a possible contribution of HSP90 to bcl-2-induced
stabilization of HIF-1a, we determined whether the pharmacolog-
ical inhibition of HSP90 with 17-AAG, an inhibitor that can alter
the interaction of HSP90 with its clients [29], modulates HIF-1a
expression (Figure 6A) and transcriptional activity (Figure 6B)i n
control cells and two bcl-2 transfectants cells under hypoxia. 17-
AAG reduced hypoxia-induced HIF-1a accumulation in control
cells, while only a very barely down-regulation of HIF-1a protein
expression was evident in bcl-2 overexpressing clones after 17-AAG
treatment (Figure 6A). These results suggested that bcl-2
overexpression might confer a resistance of HIF-1a protein from
the degradation induced by the 17-AAG. On the functional level,
0.05 mM 17-AAG induced about 30% versus 10% inhibition of
HRE-dependent transcriptional activity in control cells compared
with bcl-2 transfectants. The higher dose of 2 mM completely
inhibitedHRE-dependenttranscriptionalactivityincontrol cells,by
contrast bcl-2 transfectants cells were resistant to HRE-dependent
transcriptional activity inhibition induced by the same dose of 17-
AAG (Figure 6B). Most importantly, as shown in Figure 6C,
HSP90 protein is highly expressed in both control and bcl-2
overexpressing cells, and the impact of either bcl-2 status and either
hypoxic conditions on HSP90 protein expression was not relevant.
To provide evidence that the HSP90 is involved in bcl-2-induced
stabilization of HIF-1a, we investigated the effect of bcl-2 on the
interaction between HIF-1a and HSP90 proteins by immunopre-
cipitation of HIF-1a and Western blot analysis of HSP90 protein.
As depicted in Figure 6D, bcl-2 overexpression under hypoxia
enhanced the ability of HIF-1a to form a complex with HSP90. To
confirm the interaction between HIF-1a and HSP90 proteins, we
performed a reverse immunoprecipitation experiment from total
extract of hypoxic cells. Under these conditions, in spite of similar
levels of immunoprecipitated HSP90, a larger amount of HIF-1a
protein within the immunoprecipitate was found in total extracts of
bcl-2 transfectants (Figure 6E), confirming a stronger interaction
between HIF-1a andHSP90 proteinsinbcl-2 transfectants.Wealso
studied the interaction between HSP90 and bcl-2 protein under
hypoxic conditions and we found that HSP90 was associated with
ectopic bcl-2 protein (Figure 6E). Similar results were also
observed when immunoprecipitation experiments were carried
out in nuclear extracts (data not shown). These findings suggest that
bcl-2 may promote stabilization of HIF-1a by increasing its ability
to interact with the HSP90 chaperone complex. To gain insight to
these results, we investigated whether the bcl-2/HSP90/HIF-1a
binding could be reversed when exposing the cells to 17-AAG. We
found that 17-AAG treatment reduced the binding between HSP90
and HIF-1a only in control cells and weakly in bcl-2 transfectants,
confirming that bcl-2 overexpressing cells were more resistant to 17-
AAG-induced degradation of HIF-1a. Moreover, we found that the
interaction of bcl-2 protein with HIF-1a was not affected by 17-
AAG treatment (Figure 6F). Because our results showed that both
HSP90 and HIF-1a proteins bind to bcl-2, we investigated the
potential formation of a HSP90/HIF-1a/bcl-2 tri-complex. To
address this hypothesis, the cell lysates were firstly immunoprecip-
itated with anti-HIF-1a antibody, then subjected to a second
immunoprecipitation with anti-bcl-2 antibody, and the immuno-
complexes were analyzed by Western blot analysis using antibody
against HSP90 protein. As shown in Figure 6G, HSP90 could be
found in complex with HIF-1a and bcl-2 protein in cells
overexpressing bcl-2, demonstrating the formation of a HSP90/
Figure 5. HIF-1a prolyl hydroxylation is not required for bcl-2-induced increase of HIF-1a expression and HIF-1 activity in hypoxia.
(A) Western blot analysis of HIF-1a, bcl-2 and PHD2 protein expression and (B) HRE-dependent transcriptional activity in M14 cells stably expressing
HA-HIF-1a wild-type (HIF1a wt) or mutated (HIF1a PP/AA), after transiently transfection with control vector (empty), bcl-2 or PHD2 expressing vectors,
and then exposure to hypoxia for 24 h. (A) b-actin protein amounts are used to check equal loading and transfer of proteins. Western blot analyses
representative of two independent experiments with similar results are shown. (B) Relative luciferase activity of each sample were normalized to the
control vector transfected cells. Results represent the mean 6 SD of 3 independent experiments performed in triplicate, * p#0.01.
doi:10.1371/journal.pone.0011772.g005
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bcl-2 may promote stabilization of HIF-1a by increasing its ability
to interact with the HSP90 chaperone complex, probably affecting
its folding and maturation.
HSP90b isoform is the mediator of HIF-1a induction by
bcl-2 under hypoxic conditions
The molecular chaperones HSP90 comprise two homologous
proteins, HSP90a and HSP90b, that are encoded by distinct genes
Figure 6. bcl-2 forms a complex with HSP90 and HIF-1a proteins. (A) Western blot analysis of HIF-1a protein expression in M14 control cells
(puro) and bcl-2 stably overexpressing (Bcl2/5, Bcl2/37) clones treated with 17-AAG under hypoxia or exposed to normoxia for 24 h. (B) HRE-
dependent transcriptional activity in the cells treated with 17-AAG from 0.05 to 2 mM under hypoxia or exposed to normoxia for 24 h. Relative
luciferase activity of each sample was normalized to untreated cells exposed to normoxic conditions. Results represent the average 6 SD of 3
independent experiments performed in triplicate. p values were calculated relative to untreated cells exposed to hypoxic conditions, *p#0.01. (C)
Western blot analysis of HSP90 protein expression in parental M14 cells, control (puro) and bcl-2 stably overexpressing (Bcl2/5, Bcl2/37) clones. (D)
Analysis of HIF-1a/HSP90 interaction in the cells exposed to hypoxia for 24 h. Whole cell lysates were immunoprecipitated (IP) with anti-HIF-1a or
control (IgG) antibodies and then the Western blot analysis was performed using anti-HSP90 and anti-HIF-1a antibodies. (E) Analysis of HSP90/HIF-1a
and HSP90/bcl-2 interactions in the cells exposed to hypoxia for 24 h. Cell lysates were immunoprecipitated (IP) with anti-HSP90 or control (IgG)
antibodies and then the Western blot analysis was performed using anti-HIF-1a, anti-bcl-2 and anti-HSP90 antibodies. (F) Analysis of HIF-1a/HSP90
and HIF-1a/bcl-2 interactions in the cells treated with 0.5 mM 17-AAG for 24 h under hypoxia. Whole cell lysates were immunoprecipitated (IP) with
anti-HIF-1a antibody and then the Western blot analysis was performed using specific anti-HSP90 and bcl-2 antibodies. (G) Analysis of HSP90/HIF-1a/
bcl-2 protein complex in the cells exposed to hypoxia for 24 h. Whole cell lysates were sequentially immunoprecipitated with anti-HIF-1a (IP1) and
anti-bcl-2 antibodies (IP2) and then the Western blot analysis was performed using anti-HSP90 antibody. (A,C) b-actin protein amounts are used to
check equal loading and transfer of proteins.
doi:10.1371/journal.pone.0011772.g006
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overexpression on the expression of these isoforms and their
binding to HIF-1a protein. We found that both the hypoxic
conditions and bcl-2 protein level of the cells did not modulate the
expression of HSP90a and HSP90b proteins (Figure 7A). We
then investigated the effect of bcl-2 on the interaction between
HIF-1a and HSP90s proteins by immunoprecipitation of HIF-1a
protein. As depicted in Figure 7B, Western blot analysis, using
antibodies specifically recognizing the isoform a or b, showed that
HSP90b, but not HSP90a, forms a complex with HIF-1a protein
in bcl-2 overexpressing cells exposed to hypoxia. To further
validate the involvement of HSP90 proteins and to confirm the
possibility that HSP90b, rather than a isoform, is involved in HIF-
1a stabilization mediated by bcl-2 in hypoxia, HIF-1a protein
expression was evaluated in bcl-2 overexpressing cells after
transfection with shRNA targeting the a (shHSP90a) or the b
(shHSP90b) isoforms. As control, cells were transfected with
scramble shRNA vector (shNC).
Western blot analysis confirmed the effective knockdown of the
expression of each HSP90 target (Figure 7C,D). Moreover, the
specificity of each shRNA against HSP90 was demonstrated by the
absence of expression modulation of the other HSP90 isoform,
verifying that both shRNAs were highly specific for their respective
targets. Interestingly, Western blot analysis showed that shHSP90b
(Figure 7C), but not shHSP90a (Figure 7D), completely
inhibited hypoxic induction of HIF-1a protein in bcl-2 overex-
pressing cells.
Discussion
The bcl-2 protein is an inhibitor of apoptosis that has been
recognized to play an important role also in a wide range of other
biological processes, among which autophagy, DNA repair and
drug resistance [21,30–32]. Recent studies, including ours, have
demonstrated that bcl-2 also promotes tumour progression and
angiogenesis of different tumour histotypes [13,16,33,34]. In this
context, we have previously demonstrated that under hypoxic
conditions the overexpression of bcl-2 in tumour cells is able to
increase tumor angiogenesis enhancing the secretion of the pro-
angiogenic factor VEGF, through the induction of HIF-1a protein
expression and HIF-1 transcriptional activity [12,13].
In the present study, we investigated the mechanism by which
bcl-2 regulates HIF-1a protein expression in M14 melanoma cells
under conditions strictly dependent on oxygen availability, such as
hypoxia and high cell density. We demonstrated that HIF-1a
protein is required for bcl-2-induced VEGF expression under
hypoxia by using a small interference approach. Moreover, we
confirmed the capability of bcl-2 to modulate VEGF expression in
several melanoma cells. We showed that also in high cell density
conditions, which create a local pericellular hypoxic microenvi-
ronment, bcl-2 overexpression determines an increase of HIF-1a
protein expression and HIF-1 transcriptional activity, similar to
the ones obtained in hypoxia. Alternatively, bcl-2 is not able to
cooperate with insulin or EGF to induce HIF-1a protein
expression under normoxia, highlighting that the capacity of bcl-
Figure 7. HSP90b is the mediator of HIF-1a induction by bcl-2 under hypoxic conditions. (A) Western blot analysis of HSP90a and HSP90b
protein expression in M14 control (puro) and bcl-2 stably overexpressing (Bcl2/5, Bcl2/37) clones exposed to hypoxia or to normoxia for 24 h. (B)
Analysis of HSP90a/HIF-1a and HSP90b/HIF-1a interactions in the cells exposed to hypoxia for 24 h. Protein extracts were immunoprecipitated (IP)
with anti-HIF-1a and then Western blot analysis was performed using anti-HSP90a and anti-HSP90b antibodies. (C,D) Western blot analysis of HIF-1a,
HSP90a and HSP90b protein expression in bcl-2 stably overexpressing cells transiently transfected with short hairpin construct targeting HSP90b
(shHSP90b), HSP90a (shHSP90a) or with control vector (shNC) and exposed to hypoxia or to normoxia for 24 h. (A,C,D) b-actin protein amounts are
used to check equal loading and transfer of proteins. (A–D) Western blot analyses representative of two independent experiments with similar results
are shown.
doi:10.1371/journal.pone.0011772.g007
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availability.
We further identified HIF-1a protein stabilization as a key
mechanism for HIF-1 induction by bcl-2 under hypoxia. Our
data demonstrated that bcl-2 under this condition affects HIF-
1a protein at the post-translational level, indeed the degradation
rate of HIF-1a protein was faster in the control cells than in bcl-
2 transfectants. Although under normoxia this HIF-1a stabili-
zation is not sufficient to affect the steady state levels of the
protein, it becomes rate limiting during hypoxia or, in general,
in conditions strictly dependent on oxygen level. In fact, we
found that bcl-2 overexpression determines an increase of HIF-
1a protein half-life also in high cell density conditions, as
observed under hypoxia. The stabilization of HIF-1a protein in
response to changes in oxygen concentration is achieved
through the impairment of HIF-1a ubiquitination and subse-
quent degradation of the protein. Generally, HIF-1a is
degraded in an oxygen-dependent manner through the activity
of PHD2 enzyme, which hydroxylates HIF-1a on proline
residues 402 and 564, and this hydroxylated form is bound by
the E3 ubiquitin ligase VHL which promotes HIF-1a ubiqui-
tination and its subsequent proteasomal degradation [19].
Notwithstanding, we found that bcl-2 regulates HIF-1a protein
stability in a prolyl hydroxylation-independent manner since
bcl-2 overexpression had similar effects on either wild type
protein and the degradation resistant form of HIF-1a, which
contains proline-to-alanine substitutions (P402A/P564A) trig-
gering a resistance to PHD2-mediated hydroxylation. In
agreement with this finding, in our experimental model PHD2
protein expression was upregulated in response to hypoxia at
comparable levels in parental cells and bcl-2 overexpressing
clones (data not shown). Further, bcl-2 overexpression had no
impact on HIF-1a protein stabilization induced by iron
antagonists known to inhibit hydroxylase activity, such as
Cobalt Chloride and Desferoxamine.
Some authors have reported that bcl-2 may reside, and even
elicit a function, within the nucleus [21–23], modulating the
transactivity of several transcription factors [35,36]. Here, we
present evidence that in our experimental model the exogenous
bcl-2 protein is also localized in the nucleus, beyond the
cytoplasm. Of note, our results reveal, for the first time, that bcl-
2 protein interacts with HIF-1a in the nucleus, thus the pro-
angiogenic effect of bcl-2 on HIF-1/VEGF axis may result from
the nuclear localization of bcl-2. Since the HIF-1a/bcl-2 complex
can be observed in the nucleus, we can speculate that bcl-2-
mediated stabilization of HIF-1a protein occurs in this cellular
compartment. By dissecting the molecular mechanism of this
process, we found that bcl-2 increases HIF-1a protein stability
through the involvement of the molecular chaperone HSP90,
which was found to protect HIF-1a from proteasomal degrada-
tion, even in VHL-deficient cells [37,38]. In this context, our data
further indicate that the enhanced levels of HIF-1a protein in bcl-
2 overexpressing clones may be due to a decreased poly-
ubiquitination of HIF-1a by enforcing the interaction between
HIF-1a and HSP90 protein. Moreover, we have shown not only a
novel association of HIF-1a with bcl-2, but we have also observed
that bcl-2 is able to interact with HSP90 itself. Most importantly,
we found that the interaction between bcl-2 and HIF-1a proteins
was not dependent on HSP90 inhibition, because the binding of
bcl-2 and HIF-1a was not reversed by the treatment with 17-
AAG. In addition, sequential immunoprecipitation experiments
demonstrated that bcl-2, HIF-1a and HSP90 proteins may form a
tri-complex which probably contributes to enhance HIF-1a
protein stability in bcl-2 overexpressing clones under hypoxia.
Here, we investigated the role of HSP90a and HSP90b isoforms in
bcl-2-mediated HIF-1a induction under hypoxic condition. These
two homologous proteins display some differences and elicit
specific functions, such as differential binding to client proteins
[28]. Using genetic approaches to specifically knockdown each
HSP90 isoform in bcl-2 overexpressing cells, we found that
HSP90b, but not HSP90a, is required for HIF-1a protein
stabilization by bcl-2. Moreover, in agreement with these data,
we found that only HSP90b binds HIF-1a protein in bcl-2
overexpressing cells exposed to hypoxia. These results are in a
good accordance with very recent data demonstrating an
association between b isoform of HSP90 and bcl-2 protein in
response to VEGF in leukemia cells [39] or to CpG oligodeox-
ynucleotide in macrophages [40]. All together, these results
confirm that HSP90b is an important regulator of HIF-1a
stability and indicate that this molecular chaperone may be one
of the mediators of bcl-2 pro-angiogenic function. A recent report
demonstrated that RACK1 protein promotes ubiquitination of
HIF-1a induced by the HSP90 inhibitor 17-AAG and its
subsequent VHL-independent proteasomal degradation compet-
ing with HSP90 for binding to PAS domain of HIF-1a [2].
Notwithstanding, when exposing melanoma cells to the HSP90
inhibitor 17-AAG, we observed that bcl-2 overexpression
counteracts both HIF-1a protein degradation induced by 17-
AAG, and the reduction of interaction between HIF-1a and
HSP90 induced by the inhibitor. Besides, we did not observe any
difference in the HIF-1a binding to RACK1 after forced
expression of bcl-2 under hypoxia even after 17-AAG exposure
(data not shown), suggesting that bcl-2 does not regulates
RACK1/Elongin-C dependent HIF-1a degradation pathways.
So far we cannot exclude that other molecular players, such as
HSP70, JNK1 and the COMMD1 proteins [41–43], may be
modulated by bcl-2 and play a role in the stabilization process of
HIF-1a protein mediated by bcl-2.
In conclusion, our study establishes a molecular link and
highlights the possibility that bcl-2 is a new HIF-1a-binding
protein whose multivalent interactions are required for the
stabilization of HIF-1a, and that nuclear localization of bcl-2
may have an important role in protecting HIF-1a from
ubiquitination and proteasomal degradation that commences in
the nucleus.
Materials and Methods
Cell cultures, hypoxia exposure, transfections and viral
infection
Human melanoma cell lines were cultured in complete RPMI
medium (Invitrogen, Carlsbad, CA). JR1, JR8, M14, PLF2 [44],
and ASM-SC, bcl-2 overexpressing clones (Bcl2/5 and Bcl2/37)
and a control clone (puro) derived from the M14 line after stable
transfection, bcl-2 overexpressing (JR8/Bcl-2 and PLF2/Bcl-2)
and control (JR8/puro, PLF2/puro) cells derived from the JR8
and PLF2 line after stable transfection were used. ASM-SC was
cloned by limiting dilution from A375.S2 melanoma cell line
(ATCC, Manassas, VA). For hypoxia exposure, culture dishes
were placed in a hypoxia chamber allowing the formation of a
hypoxic environment of 5% CO2, 95% N2. Unless stated
otherwise, these hypoxic levels (1% of oxygen concentration,
24 h) was used in all experiments. For experiments under low or
high cell density conditions, 100 cells/mm
2 or 700 cells/mm
2 were
respectively plated and 24 h later cells were harvested and
subjected to different assays.
The cells were stably or transiently transfected with the
expression vector encoding the human wild type bcl-2. Transfec-
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previously reported [44], using Lipofectamine (Invitrogen).
SureSilencing shRNA plasmids against HSP90a and b isoforms
containing the hygromycin resistance gene were obtained from
SABiosciences (Frederick, MD). Polyclonal population of stably
transfected cells were used. Viruses were generated as previously
described [45]. In short, the Phoenix amphotropic packaging line
was transfected with the pBabe-based retroviral expression vectors
carrying wild type (Addgene plasmid 19365) or hydroxylation-
resistant (P402A/P564A) form (Addgene plasmid 19005) of HA-
tagged HIF-1a. Transfected cells were incubated for 48 h at 37uC
for virus production. The virus-containing medium was collected,
filtered and used to infect the target cells. Stable clones or mixed
populations were cultured in the presence of puromycin (1 mg/ml).
Reagents
Cyclohexamide (CHX), Z-leu-leu-leu-CHO (MG132), Cobalt
Chloride (CoCl2), Desferrioxamine (DFO), 17-Allylamino-17-
demethoxy-geldanamycin (17-AAG), insulin, Epidermal Growth
Factor (EGF) were purchased from Sigma-Aldrich (St. Louis, MI,
USA).
Isolation of nuclear/cytoplasmic fractions
Nuclear and cytoplasmic fractions were prepared as follows: 1–
2610
6 cells were resuspended in a hypotonic lysis buffer (10 mM
HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA)
containing protease inhibitors (Boehringer). After resuspension,
NP-40 was added to a final concentration of 0.6% and the nuclei
were isolated by centrifugation at 10,000 r.p.m. for 30 s at 4uC.
After removing the supernatant (i.e. the cytoplasmic extract), the
nuclei were re-suspended in a nuclear extract buffer (20 mM
HEPES pH 7.9, 25% glycerol, 0.4 M NaCl, 0.1 mM EDTA,
0.1 mM EGTA), rocked for 15 min at 4uC and then recovered by
centrifugation at 140,00 r.p.m. for 5 min at 4uC.
Immunoprecipitation and Western blot analysis
For immunoprecipitation assays and Western blot analysis, the
cells were lysed in 0.3% CHAPS buffer (40 mM HEPES [pH 7.5],
120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM
glycerophosphate, 50 mM NaF, 1.5 mM Na3VO4, 0.3% CHAPS,
and one tablet EDTA-free protease inhibitors [Roche] per 10 ml).
Followed by centrifugation, the supernatant was precleared with
protein A/G agarose beads coupled with mouse or rabbit IgG
(Pierce, Thermo Fisher Scientific, Rockford, IL) for .2 h and then
was exposed to 1 mg of the antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) or mouse or rabbit IgG, as control, was added to
each of the cellular lysates and incubated overnight at 4uC
followed by incubation with protein A/G-agarose beads (Amer-
sham Biosciences Europe, Milan, Italy) for 2 h at 4uC.
Immunoprecipitates were washed four times in the lysis buffer
before Western blotting analysis. For some immunoprecipitation
experiments we used ExactaCruz
TM reagents (Santa Cruz
Biotecnology) to detect the bcl-2 protein without detection of the
light chain of the immunoprecipitation antibody. Immunoprecip-
itation were also performed using multiple antibodies recognizing
different epitopes on the bcl-2 (Santa Cruz Biotecnology) and HIF-
1a (Santa Cruz Biotecnology; Novus Biologicals, Littleton, CO)
protein. Sequential immunoprecipitation experiments were per-
formed incubating 2 mg of total cell lysate with antibody as for
single immunoprecipitation, after washing the precipitated pro-
teins were released with 1% SDS at 37uC for 30 minutes. Then,
the eluate was diluted to a final concentration of 0.1% SDS with
lysis buffer and immunoprecipitation was repeated with the
supernatant with fresh beads and antibody.
For Western blot analysis, antibodies directed to HIF-1a, HIF-
1b, HSP90 (BD Pharmingen), HA epitope, ubiquitin (Santa Cruz
Biotecnology), bcl-2 (Dako, Milan, Italy), b-tubulin (Thermo
Scientific), HSP90a, HSP90b (Abcam, Cambridge, UK), PHD2
(Novus Biologicals), Lamin A/C (Cell Signaling, Danvers, MA), b-
actin (Sigma) were used.
Pulse and pulse-chase assays
In the pulse assay, cells were incubated with methionine/
cysteine–free serum-free DMEM (Invitrogen) for 2 h. [
35S]-
labeled methionine-cysteine (88 mCi/ml, EasyTag
TM EX-
PRESS
35S Protein Labeling Mix, PerkinElmer, Waltham,
MA) was added to the medium and cells were collected after
15 and 45 min. In the pulse-chase assay, after 45 min pulse
with [
35S]-labeled methionine-cysteine, cells were washed three
times with PBS, chased with DMEM containing 10% FBS and
2.5 mg/mL cold L-methionine and harvested after 15, 30, 45
and 60 min. Total protein lysates from pulse and pulse-chase
assays were immunoprecipitated by HIF-1a antibody. Radio-
labeled HIF-1a protein and the input cell lysates were subjected
to SDS-PAGE. Gels were dried, exposed in phosphorImager
cassette for 1–3 days and imaged using Personal Molecular
Imager FX and Quantity OneH software (Biorad Laboratories,
Hercules, CA).
ELISA
The supernatants were harvested and assayed for VEGF
content by ELISA kit according to the manufacturer’s instructions
(R&D Systems, Minneapolis, MN). VEGF levels were normalized
to the number of adherent cells.
Reporter gene assay
The cells were seeded in 24-well plates and were transfected
with a total of 1 mg of DNA/well using Lipofectamine reagent.
The evaluation of HIF-1 transcriptional activity was performed as
previously described [12] transfecting cells with a vector expressing
luciferase under the control of 4X Hypoxia Responsive Element
(HRE) and another one expressing b-galactosidase under the
control of CMV promoter. The relative luciferase activity was
calculated by luciferase/b- galactosidase ratios for each sample.
Confocal analysis
After 24 h hypoxic conditions exposure, cells were fixed in
100% methyl alcohol for 10 min at 220uC and then incubated
with primary antibodies. The cells were incubated with TRITC
conjugated Goat anti-Rabbit and/or FITC conjugated Goat anti-
Mouse (Jackson Lab, West Grove, PA). Nuclei were visualized
using TO-PRO3H (Invitrogen). The images were scanned under a
640 oil immersion objective and to avoid bleed-through effects,
each dye was scanned independently by a Leica confocal
microscope (laser-scanning TCS SP2) equipped with Ar/ArKr
and HeNe lasers. The images were acquired and electronically
merged utilizing the Leica confocal software (Leica Microsystems
Heidelberg GmbH, Mannheim, Germany). Figures were pro-
cessed using Adobe PhotoShop software.
Densitometric analysis
Developed films were acquired using GS-700 Imaging Densi-
tometer (Biorad) and processed with Corel Photo Paint 7.0 to
adjust image brightness and contrast. Densitometric evaluation
was performed using Molecular Analyst Software (Biorad) and
normalized with relative controls depending on the analysis
performed.
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Differences between groups were analyzed with a two-sided
paired or unpaired Student’s t test by use of GraphPad Prism 3.00
(GraphPadSoftware, San Diego, CA). Results were considered to
be statistically significant if p,0.05. Experiments were usually
repeated three times unless indicated otherwise.
Supporting Information
Figure S1 HIF-1a protein is required for VEGF induction by
bcl-2 in melanoma cells under hypoxia. (A) Western blot analysis
of bcl-2 protein expression in whole extracts and (B) ELISA assay
of VEGF protein in conditioned medium in several human
melanoma cell lines exposed to normoxia and hypoxia for 24 h,
after transient transfection with control (empty) or bcl-2
expressing vector (Bcl-2). (C) Western blot analysis of HIF-1a
and HIF-1b protein expression in total extracts and (D) ELISA
assay of VEGF protein in conditioned medium in M14 cells
stably transfected with control (puro) or bcl-2 expression vector
(Bcl2/5) after transfection with siRNA directed against HIF-1a
(siHIF-1a) or unrelated control mRNA (siNC) and then exposed
to normoxia or hypoxia for 24 h. (A,C) b-actin protein amounts
are used to check equal loading and transfer of proteins. Western
blot analyses representative of two independent experiments with
similar results are shown. (B,D) Results represent the mean 6 SD
of 3 independent experiments performed in triplicate. Fold
induction of secreted VEGF protein relative to normoxia.
*p ,0.01
Found at: doi:10.1371/journal.pone.0011772.s001 (0.98 MB TIF)
Figure S2 Bcl-2 cooperates with high cell density conditions to
induce nuclear HIF-1a protein and HIF-1 transactivation activity.
(A) Western blot analysis of HIF-1a and HIF-1b protein
expression in cytoplasmic (Cyto) and nuclear (Nucl) protein
extracts of M14 control (puro) and bcl-2 overexpressing (Bcl2/5,
Bcl2/37) cells plated under low (sparse) or high (dense) cell density
condition. b-actin protein amounts are used to check equal loading
and transfer of proteins. Western blot analysis representative of
two independent experiments with similar results are shown. (B)
HRE transcriptional activity of the cells cultured under sparse or
dense conditions. Results represent the mean 6SD of 3
independent experiments performed in triplicate. Fold induction
relative to sparse condition. * p,0.01
Found at: doi:10.1371/journal.pone.0011772.s002 (0.88 MB TIF)
Figure S3 Bcl-2 promotes HIF-1a protein stability in high cell
density conditions. Western blot analysis (panel left) and
quantification (panel right) of HIF-1a protein expression in total
lysates of melanoma control (puro) and bcl-2 overexpressing (Bcl2/
5, Bcl2/37) cells cultured under high cell density conditions (dense)
and then treated with Cyclohexamide (CHX, 50 mg/ml) for the
indicated times. b-actin protein amounts are used to check equal
loading and transfer of proteins. Western blot analysis represen-
tative of two independent experiments with similar results are
shown. Densitometric analysis (panel right) of the relative Western
blot (panel left) was performed using Molecular Analyst Software
and normalized with relative controls depending on the analysis
performed.
Found at: doi:10.1371/journal.pone.0011772.s003 (0.89 MB TIF)
Figure S4 Bcl-2 does not cooperate with hypoxic mimetic
compounds to induce HIF-1a protein expression. Western blot
analysis of HIF-1a protein expression in total lysates of M14
control (puro) and bcl-2 overexpressing (Bcl2/5, Bcl2/37) cells
exposed to desferrioxamine (DFO, 50 mM) or Cobalt Cloride
(CoCl2, 100 mM) for 3 h. b-actin protein amounts are used to
check equal loading and transfer of proteins. Western blot analyses
representative of two independent experiments with similar results
are shown.
Found at: doi:10.1371/journal.pone.0011772.s004 (0.39 MB TIF)
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